Opticeutical Inc.
Built on Science.
The Company
Opticeutical Inc. is a product family of Atumnus, a longevity platform company. Co-founded by Daniel Nowak (Chief Technology Officer) and Daniel William Dorsey (Chief Executive Officer). Incorporated to bring published bioregulator peptide science to consumers without a prescription barrier.
Intellectual Property
Proprietary bioregulator formulations protected across multiple provisional patent applications. Patent pending. Additional protection across formulation, delivery system, and method-of-use domains.
Manufacturing
Manufactured at an established cGMP facility with multi-decade operational history and substantial dedicated production capacity. Manufacturing partnership active.
Research Foundation
All formulas are built on published peer-reviewed research. The HelioMend research library cites every primary source. Over 800 publications from the Khavinson Institute underpin the bioregulator science.
Three doors.
One company.
Clinical & Wholesale
HelioMend Reconstruct™ is dispensed through licensed practitioners. Wholesale and practitioner-direct accounts are accepted on application.
Practitioner Inquiry →Editorial & Media
For press inquiries, interview requests, or editorial collaboration on bioregulator peptide research, contact the Opticeutical communications desk.
Press Inquiry →Strategic Inquiries
Atumnus is open to qualified strategic partners and investors aligned with the longevity and consumer health platform thesis. Data room access is provided on request.
Partner Inquiry →